Alembic Pharma gets form 483 with five procedural observations by USFDA
The GMP inspection was conducted at the company’s Jarod facility
The United States Food and Drug Administration inspected Alembic Pharmaceuticals’ Solid Oral Formulation Facility (F-4) at Jarod.
The scheduled GMP inspection was conducted from November 14, 2024, to November 22, 2024. The USFDA issued a Form 483 with five procedural observations.
- Advertisement -